Stocks and Investing Stocks and Investing
Thu, January 4, 2024
Wed, January 3, 2024
Tue, January 2, 2024

Jason Gerberry Maintained (ARWR) at Strong Buy with Increased Target to $37 on, Jan 2nd, 2024


Published on 2024-10-28 08:09:33 - WOPRAI, Jason Gerberry
  Print publication without navigation


Jason Gerberry of B of A Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $29 to $37 on, Jan 2nd, 2024.

Jason has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Thursday, November 30th, 2023
  • Shawn Egan of "Citigroup" Initiated at Hold and Held Target at $33 on, Tuesday, September 19th, 2023


This is the rating of the analyst that currently disagrees with Jason


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Thursday, November 30th, 2023